Article

Endocrine therapy passion gives three researchers rock star status

Author(s):

This afternoon I attended a general session at SABCS where Susan G. Komen for the Cure awarded the Brinker Awards for Scientific Distinction to three researchers for their work in endocrine therapy. Huh? Ok, first, let me give you a definition of what endocrine therapy is. According the the National Cancer Institute, endocrine therapy is:Treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body's natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called hormonal therapy, hormone therapy, and hormone treatment.The awards went to Geoffrey L. Greene, PHD of the University of Chicago, Benita Katzenellenbogen, PHD, University of Illinois-Urbana Champaign, and Professor Ian Smith of the Royal Marsden Hospital of London. In a nutshell, their combined resarch revolves around understanding estrogen receptors and how we can provoke them respond to treatment. I'm no scientist, and I promise to stick to "color commentary" from this point forward, but what I can tell you is these guys are heavy hitters. They have not only changed the way cancer is dianosed and treated, but also how outcomes can be predicted. In a packed hall with hundreds of docs hanging on every word, each researcher told the audience about their work in endocrine therapy. Dr. Greene's research determined that receptors exist. Dr. Katzenellenbogen's reseach focused on how receptors respond to various hormones. Dr. Smith's research involved early clinical development of anti-cancer drugs based on this research. One of the first questions doctors want to know when assessing treatment options for their patients is whether the tumor is ER positive or negative. The answer will determine which treatment pathway to follow. This reasearch will also help doctors determine which patients will (and won't) respond to chemotherapy. More on that tomorrow.The cure to cancer is complicated, but tonight's award-winners have helped us better understand this deadly disease by finding ways to trick hormones into working with us instead of against us.

Related Videos
Dr. David A. Braun, an Assistant Professor of Medicine, Medical Oncology, and a Louis Goodman and Alfred Gilman Yale Scholar, at the Yale School of Medicine, as well as a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, in New Haven, Connecticut
1 expert is featured in this series.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
1 expert is featured in this series.
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Related Content